FDA refuses to review Moderna flu vaccine / Beckers

Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

Moderna's flu shot dilemma muddies 2028 break-even guidance

4 wks / endpoints / Max Bayer

The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen

4 wks / oncodaily

PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna

4 wks / endpoints / Ayisha Sharma

FDA rejects Moderna's mRNA flu vaccine application, for reasons with no basis in the law

4 wks / medicalxpress

What the Health? From KFF Health News: New Flu Vax? FDA Says No Thanks

4 wks / kffhealthnews

Controversy around FDA’s Prasad rises again after Moderna rejection, behavior allegations

4 wks / endpoints / Zachary Brennan

Jeff Coller: The FDA Just Refused to Review Moderna’s mRNA Influenza Vaccine Application

4 wks / oncodaily

FDA may consider Moderna's flu vaccine in a narrower group

4 wks / endpoints / Max Bayer

U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine

4 wks / nytimes / Christina Jewett

Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance

4 wks / medcitynews / Frank Vinluan

Prasad overruled vaccine review team, office director on Moderna flu shot

4 wks / endpoints / Zachary Brennan

FDA refuses to review Moderna flu vaccine

4 wks / beckershospitalreview / Ella Jeffries

FDA refuses to review Moderna’s mRNA flu vaccine

4 wks / healthcaredive / Delilah Alvarado

F.D.A. Refuses to Review Moderna Flu Vaccine

4 wks / nytimes / Christina Jewett and Rebecca Robbins

Moderna accuses FDA of shifting standard as agency refuses flu shot review

4 wks / endpoints / Max Bayer

Wednesday, February 11, 2026, 10:25 am / permalink 19026 / 15 stories in 4 wks

StackHealth Time Machine

Outgoing Stories

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours

Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours

FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours

HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours

Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours

AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours

More StackHealth

Bluesky: